Aetna modified CPB 0982 for remdesivir (Veklury) coverage, effective January 15, 2026. Here's what billing teams need to know before submitting claims.
Aetna, a CVS Health company, updated its Veklury coverage policy under CPB 0982 Aetna system, tightening the eight-criterion checklist for outpatient COVID-19 treatment. The change directly affects HCPCS code J0248 (remdesivir, 1 mg per injection) and infusion billing under CPT codes 96365–96368. If your practice treats high-risk, non-hospitalized COVID-19 patients and bills Aetna commercial plans, this policy change affects your reimbursement and claim denial exposure starting January 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Remdesivir (Veklury) — CPB 0982 |
| Policy Code | CPB 0982 |
| Change Type | Modified |
| Effective Date | January 15, 2026 |
| Impact Level | Medium |
| Specialties Affected | Infectious disease, internal medicine, primary care, infusion therapy, urgent care |
| Key Action | Confirm all eight medical necessity criteria are documented before submitting J0248 claims to Aetna commercial plans |
Aetna Remdesivir Coverage Criteria and Medical Necessity Requirements 2026
CPB 0982 is Aetna's clinical policy bulletin governing remdesivir (Veklury) coverage for commercial medical plan members. This is an outpatient-only policy. Hospitalized members receiving Veklury for COVID-19 fall under their inpatient benefit — not CPB 0982. Do not use this policy to guide inpatient billing.
For outpatient claims, Aetna considers remdesivir medically necessary only when all eight criteria below are met simultaneously. Every single one is required. Missing even one criterion is enough to trigger a claim denial.
Here's what Aetna requires:
1. Confirmed active COVID-19 infection. The member must have a confirmed, active infection — not a suspected case or recent exposure.
2. Weight of at least 1.5 kg. This is a pediatric-relevant threshold, but it applies across all age groups under this coverage policy.
3. At least one active symptom within seven days before treatment. Aetna's policy lists fever, cough, fatigue, shortness of breath, sore throat, headache, and myalgia/arthralgia as qualifying symptoms. The symptom must be ongoing — not resolved before treatment starts.
4. Non-hospitalized status with high-risk features. The member must be at risk for progression to severe COVID-19. Aetna's policy lists chronic lung disease, diabetes mellitus, obesity (BMI above 30), and heart conditions as examples. This is not an exhaustive list, but document the specific risk factor clearly in the record.
5. Pre-treatment lab work completed. Hepatic function (CPT 80076) and prothrombin time (CPT 85610 or 85611) must be assessed before starting remdesivir. Monitoring must continue during therapy as clinically appropriate. If these labs aren't in the chart, your prior authorization request — and your claim — are at risk.
6. Total therapy duration of three days or fewer per infection. Aetna will not cover more than three days of remdesivir for a single COVID-19 infection. This is consistent with the FDA-approved outpatient dosing regimen, but your infusion billing under CPT 96365–96368 must reflect this limit.
7. No concurrent chloroquine or hydroxychloroquine. Remdesivir cannot be administered alongside chloroquine hydrochloride (HCPCS J0390) or hydroxychloroquine. If a member is on either drug, this coverage policy does not apply until that combination is resolved.
8. Anaphylaxis management capability at the treatment site. The infusion must occur in a setting equipped to manage severe hypersensitivity reactions, including anaphylaxis. Document the facility's capability. This matters for prior authorization and for defending a claim if it's audited.
The Aetna remdesivir coverage policy does not mention prior authorization explicitly in the CPB text. That said, given the specificity of the eight-criterion checklist and the lab requirements, check current Aetna prior auth requirements for J0248 before the first infusion. Prior auth requirements can exist at the plan level even when the CPB doesn't spell them out.
Aetna Remdesivir Exclusions and Non-Covered Indications
Aetna draws a hard line here. All indications for remdesivir outside of COVID-19 treatment in non-hospitalized, high-risk members are considered experimental, investigational, or unproven.
There are no other covered indications under this policy. If your team is billing J0248 for any other diagnosis or clinical scenario under an Aetna commercial plan, expect denial.
The real issue is that COVID-19 ICD-10 coding matters here. Aetna's applicable diagnosis codes are U07.1 (COVID-19) and J12.82 (pneumonia due to coronavirus disease 2019). If you're billing J0248 under any other diagnosis code, this policy provides no coverage support.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| COVID-19 treatment — non-hospitalized, high-risk, all eight criteria met | Covered | J0248, U07.1, 96365–96368 | All eight criteria must be simultaneously documented; hepatic panel (80076) and PT (85610/85611) required pre-treatment |
| COVID-19 with pneumonia — non-hospitalized, high-risk | Covered | J0248, J12.82, 96365–96368 | Same eight-criterion requirement applies; J12.82 is an acceptable diagnosis code |
| Hospitalized members receiving Veklury for COVID-19 | Not covered under CPB 0982 | — | Managed under inpatient benefit; CPB 0982 does not apply |
| COVID-19 treatment concurrent with chloroquine or hydroxychloroquine | Not covered | J0390 (chloroquine) | Combination is an explicit exclusion; coverage denied if concurrent use documented |
| All other indications for remdesivir | Experimental / Investigational / Unproven | — | No covered indications exist outside COVID-19 in non-hospitalized, high-risk members |
| Remdesivir beyond three days per infection | Not covered | J0248 | Duration limit is a hard stop under this coverage policy |
Aetna Remdesivir Billing Guidelines and Action Items 2026
These are concrete steps your billing and clinical teams should take before and after the effective date of January 15, 2026.
| # | Action Item |
|---|---|
| 1 | Audit your charge capture template for J0248 before January 15, 2026. Confirm your template prompts for all eight medical necessity criteria — not just diagnosis code. A U07.1 code alone does not make a remdesivir claim billable under CPB 0982. |
| 2 | Require pre-treatment lab orders for CPT 80076 and 85610 or 85611 before every remdesivir course. If hepatic function and prothrombin time aren't ordered and documented before the first infusion, you have a medical necessity gap. Build this into your infusion therapy workflow as a hard stop. |
| 3 | Limit infusion billing to three days maximum per infection. Your billing team should flag any J0248 claim that exceeds three units or three dates of service for the same infection episode. Bill CPT 96365 for the initial infusion hour, 96366 for each additional hour of the same substance, and 96367 or 96368 if applicable for sequential or concurrent infusions. Match the infusion time documentation to the code. |
| 4 | Verify the treatment setting meets anaphylaxis management requirements. If your practice isn't equipped to handle severe hypersensitivity reactions, Veklury can't be covered under this policy. This isn't theoretical — an infusion administered at a site that can't manage anaphylaxis is a coverage exclusion, not just a clinical risk. |
| 5 | Confirm the member is not on chloroquine (J0390) or hydroxychloroquine before treatment. A concurrent medication screen should be part of every remdesivir pre-authorization workflow. If either drug is in the member's active medication list, the claim will be excluded under CPB 0982. |
| 6 | Check Aetna's current prior authorization requirements for J0248 at the plan level. CPB 0982 doesn't specify prior auth steps, but individual commercial plans can layer on PA requirements. Confirm before the first infusion, not after. If you're unsure how this applies to your specific plan mix, talk to your compliance officer before January 15, 2026. |
| 7 | Document the specific high-risk condition in the clinical note. "At risk for severe COVID-19" isn't enough. Name the condition — chronic lung disease, diabetes, obesity with BMI above 30, or heart condition. Your documentation supports medical necessity and defends the claim in audit. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Remdesivir Under CPB 0982
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J0248 | HCPCS | Injection, remdesivir, 1 mg |
Other Referenced HCPCS Codes
| Code | Type | Description | Notes |
|---|---|---|---|
| J0390 | HCPCS | Injection, chloroquine hydrochloride, up to 250 mg | Concurrent use with J0248 is an explicit exclusion under CPB 0982 |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| U07.1 | COVID-19 |
| J12.82 | Pneumonia due to coronavirus disease 2019 |
Get the Full Picture for CPT 80076
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.